Literature DB >> 12074059

Minimally invasive parathyroidectomy using the 'focused' lateral approach. I. Results of the first 100 consecutive cases.

Gaurav Agarwal1, Bruce H Barraclough, Bruce G Robinson, Tom S Reeve, Leigh W Delbridge.   

Abstract

BACKGROUND: A feasibility study of 'focused' minimally invasive parathyroidectomy (MIP) using a lateral approach was commenced in 1999. The aim of the present paper was to evaluate the effectiveness and safety of this procedure in the first 100 consecutive patients.
METHODS: This was a prospective, non-randomized case-control study. One hundred consecutive patients with primary hyperparathyroidism (mean age 63.1 years; 74 females, 26 males) who fulfilled the inclusion criteria underwent focused MIP between May 1999 and December 2000. The results for the first and last 50 consecutive patients were compared to see whether they were reflective of a learning curve. The role of intraoperative quick parathyroid hormone (QPTH) estimation was also evaluated.
RESULTS: Focused MIP was successfully completed in 93 of 100 patients, with seven conversions. Three (3.2%) of the 93 patients had persistent hyperparathyroidism. Quick PTH was measured in 81 patients and the results were true positive (for cure) in 72 patients, false negative in six patients, true negative in two patients and false positive in one patient. Transient recurrent laryngeal nerve paresis occurred in one patient. During the same time period, open parathyroidectomy was performed in 242 patients. The results were not different between the first and later 50 patients undergoing MIP, nor were the outcomes significantly different from patients undergoing open parathyroidectomy.
CONCLUSIONS: Focused MIP is a safe and effective operative approach for appropriately selected patients. Failed procedures were invariably related to shortcomings of the localization studies. Measurement of QPTH, although accurate, is unreliable in the presence of multigland disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12074059     DOI: 10.1046/j.1445-2197.2002.02310.x

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN: 1445-1433            Impact factor:   1.872


  7 in total

1.  Scan-directed mini-incision focused parathyroidectomy: how accurate is accurate enough?

Authors:  I M Shapey; S Jabbar; Z Khan; J E Nicholson; R J Watson
Journal:  Ann R Coll Surg Engl       Date:  2017-02       Impact factor: 1.891

2.  Initial surgery for benign primary hyperparathyroidism: an analysis of 1,300 patients in a teaching hospital.

Authors:  Elias Karakas; Ralph Schneider; Matthias Rothmund; Detlef K Bartsch; Katja Schlosser
Journal:  World J Surg       Date:  2014-08       Impact factor: 3.352

3.  Do intraoperative total serum and ionized calcium levels, like intraoperative intact PTH levels, correlate with cure of hyperparathyroidism?

Authors:  Roderick M Quiros; Catherine E Pesce; Goldie Djuricin; Richard A Prinz
Journal:  World J Surg       Date:  2005-04       Impact factor: 3.352

4.  Cost-effectiveness of scan-directed parathyroidectomy.

Authors:  Radu Mihai; Mary Weisters; Michael J Stechman; Fergus Gleeson; Greg Sadler
Journal:  Langenbecks Arch Surg       Date:  2008-08-01       Impact factor: 3.445

5.  Minimally invasive video-assisted parathyroidectomy (MIVAP) versus conventional parathyroidectomy for renal hyperparathyroidism: a retrospective multicenter study.

Authors:  Iurii Snopok; Richard Viebahn; Martin Walz; Panagiota Zgoura; Pier Francesco Alesina
Journal:  Updates Surg       Date:  2022-05-25

6.  Is minimally invasive parathyroid surgery an option for patients with gestational primary hyperparathyroidism?

Authors:  Cino Bendinelli; Shane Nebauer; Tuan Quach; Shaun Mcgrath; Shamasunder Acharya
Journal:  BMC Pregnancy Childbirth       Date:  2013-06-11       Impact factor: 3.007

7.  Impact of concomitant thyroid pathology on preoperative workup for primary hyperparathyroidism.

Authors:  Oleg Heizmann; C T Viehl; R Schmid; J Müller-Brand; B Müller; D Oertli
Journal:  Eur J Med Res       Date:  2009-01-28       Impact factor: 2.175

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.